Please select a location from the dropdown to view relevant share classes and investments. Your home market is currently
Don't see your home market? Change Edition

Best- and Worst-Performing Danish Stocks

Novo Nordisk and Demant rank among the best stocks in Q2 2026, while the worst include Coloplast and Royal Unibrew.

illustration of a flag with chart icons and time series lines.

The Morningstar Denmark Index rose 14.00% in the second quarter amid a rally in the consumer cyclical sector. The Denmark index tracks the performance of the top 97% of the Danish investable universe by market cap, and each quarter we screen from among the stocks in this index to find the best- and worst-performing companies. Data in this article is sourced from Morningstar Direct.

The Best-Performing Stocks of Q2 2026

  1. Pandora PNDORA
  2. Demant DEMANT
  3. Novo Nordisk NOVO B
  4. ALK-Abello ALK B
  5. ChemoMetec CHEMM

The Worst-Performing Stocks of Q2 2026

  1. Netcompany Group NETC
  2. Royal Unibrew RBREW
  3. Coloplast COLO B
  4. GN Store Nord GN
  5. Ambu AMBU B

Metrics for the Best-Performing Stocks

Pandora PNDORA

  • Sector: Consumer Cyclical
  • Industry: Luxury Goods
  • Economic Moat: Narrow

Pandora soared 65.39% in the second quarter, but was down 29.29% over the past year. The company’s stock has a Morningstar Rating of 4 stars and trades at a 13% discount to the fair value estimate of DKK 860.00.

Demant DEMANT

  • Sector: Healthcare
  • Industry: Medical Devices
  • Economic Moat: Narrow

Demant surged 38.27% in the second quarter, but shares were flat for the year, having risen only 1.32%. The company’s stock has a Morningstar Rating of 3 stars, trading near its fair value estimate of DKK 261.00.

Novo Nordisk NOVO B

  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Economic Moat: Wide

Novo Nordisk climbed 36.21% in the second quarter, but over the past year, shares were down 25.23%. Novo Nordisk has a Morningstar Rating of 3 stars, with its stock trading at an 8% discount to the DKK 343.00 fair value estimate.

ALK-Abello ALK B

  • Sector: Healthcare
  • Industry: Biotechnology
  • Economic Moat: Not Rated

ALK-Abello climbed 20.73% in the second quarter, leaving the stock up 31.39% for the past year. The company’s stock has a quantitative Morningstar Rating of 3 stars.

ChemoMetec CHEMM

  • Sector: Healthcare
  • Industry: Medical Devices
  • Economic Moat: Not Rated

ChemoMetec jumped 20.37% in the second quarter, but was still down 37.51% over the past year. The company’s stock has a quantitative Morningstar Rating of 2 stars.

Metrics for the Worst-Performing Stocks

Netcompany Group NETC

  • Sector: Technology
  • Industry: Information Technology Services
  • Economic Moat: Not Rated

Netcompany Group dropped 23.73% in the second quarter, however, shares were still up 10.16% for the past year. Shares were 26.31% lower than their last high on April 17, 2026. The company’s stock has a quantitative Morningstar Rating of 3 stars.

Royal Unibrew RBREW

  • Sector: Consumer Defensive
  • Industry: Beverages - Brewers
  • Economic Moat: Narrow

Royal Unibrew slid 14.69% in the second quarter, leaving the stock down 13.67% for the past year. Shares were 33.99% below their last high on Feb. 24, 2026. The company’s stock has a Morningstar Rating of 3 stars, trading at an 11% discount to its fair value estimate of DKK 487.00.

Coloplast COLO B

  • Sector: Healthcare
  • Industry: Medical Instruments & Supplies
  • Economic Moat: Narrow

Coloplast tumbled 13.66% in the second quarter, leaving shares down 35.53% for the past year. Stocks in the company were 42.42% below the last high on Sept. 2, 2025. Coloplast has a Morningstar Rating of 4 stars, with its stock trading at a 15% discount to the DKK 440.00 fair value estimate.

GN Store Nord GN

  • Sector: Healthcare
  • Industry: Medical Devices
  • Economic Moat: None

GN Store Nord slid 13.50% in the second quarter, leaving the stock down 10.67% for the past year. Shares were 30.69% below their last high on Aug. 22, 2025. The company’s stock has a Morningstar Rating of 4 stars, trading at a 29% discount to its fair value estimate of DKK 123.00.

Ambu AMBU B

  • Sector: Healthcare
  • Industry: Medical Devices
  • Economic Moat: Not Rated

Ambu tumbled 10.85% in the second quarter, leaving shares down 38.46% for the past year. Stocks in the company were 45.44% below the last high on Oct. 7, 2025. Ambu has a quantitative Morningstar Rating of 3 stars.

Companies that are not formally covered by a Morningstar analyst are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative star rating.

This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar's use of automation.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.